Genmab to raise about DKK 370M from employee warrants
After the increase, Genmab's share capital will total DKK 62,570,683, represented by 62,570,683 shares and votes.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
Genmab A/S will increase its share capital by 164,828 shares following the exercise of employee warrants. The shares are subscribed for cash at the disclosed prices, and proceeds to the company are approximately DKK 369.7 million. The increase represents approximately 0.2641% of the company's share capital and is made without preemption rights for existing shareholders or others.
The new shares are ordinary shares and carry dividend and other rights from subscription. They will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority; the capital increase is expected to be finalized shortly.
Key Figures
Shares in capital increase: 164,828 shares
Proceeds to the company: Approximately DKK 369.7 million
Share-capital increase: Approximately 0.2641%
+3 more
6 metrics
Shares in capital increase
164,828 shares
Employee warrant exercise
Proceeds to the company
Approximately DKK 369.7 million
Cash subscriptions for the new shares
Share-capital increase
Approximately 0.2641%
Percentage of the company's share capital
Total nominal share capital after increase
DKK 62,570,683
After the capital increase
Shares after increase
62,570,683 shares
Each share has a nominal value of DKK 1
Nominal value per share
DKK 1
Each ordinary share after the capital increase
Key Terms
employee warrants, preemption rights, nominal value, negotiable instruments
4 terms
employee warrants financial
"exercise of employee warrants"
preemption rights financial
"without any preemption rights for the existing shareholders"
Preemption rights give existing shareholders the first chance to buy newly issued shares so they can keep the same fraction of ownership. Think of it like getting first dibs on extra slices of pizza so your portion of the pie doesn’t shrink. For investors this matters because it protects voting power and value per share by preventing unexpected loss of ownership when a company issues more stock.
nominal value financial
"total nominal value of Genmab A/S' share capital"
Nominal value is the stated or face amount assigned to a financial instrument — for shares it’s the par value printed on the stock certificate, and for money or returns it can mean the number not adjusted for inflation. Think of it like a price tag on an item versus its buying power: the tag tells you the label, but not how much you can actually buy. Investors care because nominal values affect accounting, legal capital, dividend calculations and comparisons over time when inflation may distort real worth.
negotiable instruments financial
"freely transferable negotiable instruments"
Negotiable instruments are written promises or orders to pay a specific sum of money that can be transferred from one person to another—examples include checks, promissory notes, and bills of exchange—so the current holder has the legal right to collect payment. They matter to investors because they act like tradable cash or IOUs, influencing a company’s liquidity and short-term credit risk; holding or issuing them affects how quickly a business can access cash and how safe its short-term finances appear.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF NOVEMBER 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated November 10, 2026 | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: November 10, 2026
Exhibit 99.1
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
2,961 shares at DKK 1,362.5, 17,676 shares at DKK 1,615,
949 shares at DKK 1,948,
25,635 shares at DKK 2,070,
6,100 shares at DKK 2,103, 4,063 shares at DKK 2,129,
2,606 shares at DKK 2,148
34,552 shares at DKK 2,175,
11,884 shares at DKK 2,317, 8,535 shares at DKK 2,381,
2,798 shares at DKK 2,408,
953 shares at DKK 2,491,
2,014 shares at DKK 2,492,
4,309 shares at DKK 2,585,
2,525 shares at DKK 2,594,
764 shares at DKK 2,641, 27,772 shares at DKK 2,661,
399 shares at DKK 2,680,
1,563 shares at DKK 2,688, 2,402 shares at DKK 2,698,
3,290 shares at DKK 2,806, and
1,078 shares at DKK 3,172.
Proceeds to the Company are approximately DKK 369.7 million. The increase corresponds to approximately 0.2641% of the Company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No. 1493 of November 18, 2025, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 62,570,683 which is made up of 62,570,683 shares of a nominal value of DKK 1 each, corresponding to 62,570,683 votes.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com or follow
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 46 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Capital Increase in Genmab as a Result of Employee Warrant Exercise
us on LinkedIn, X, Facebook and Instagram.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 46 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||